Auromedics Pharma, Llc,., Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Auromedics Pharma, Llc,., Pharmaceutical Import Records from India — 4 Products, $5.0M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Auromedics Pharma, Llc,., — Pharmaceutical Importer Profile (2026) | 4 Products, $5.0M Trade | TransData Nexus

Auromedics Pharma, Llc,.,

Pharmaceutical Importer · United States · Advanced Antibiotics Focus · $5.0M Total Trade · DGFT Verified

Auromedics Pharma, Llc,., is a pharmaceutical importer based in United States with a total trade value of $5.0M across 4 products in 3 therapeutic categories. Based on 100 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Auromedics Pharma, Llc,., sources from 1 verified Indian supplier, with Eugia Pharma Specialities Limited accounting for 100.0% of imports.

Auromedics Pharma, Llc,., — Import Portfolio & Supplier Network

Auromedics Pharma, Llc,., import network — 4 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Auromedics Pharma, Llc,.,?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Eugia Pharma Specialities Limited	$250.0K	5	100.0%

Auromedics Pharma, Llc,., sources from 1 verified Indian supplier across 4 distinct formulations. The sourcing is highly concentrated — Eugia Pharma Specialities Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Import Portfolio — Top 4 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Ertapenem	Advanced Antibiotics	$2.5M	50	2.3%	3
2	Meropenem	Advanced Antibiotics	$2.2M	44	0.7%	6
3	Pemetrexed	Advanced Oncology	$200.0K	4	0.7%	9
4	Cyclophosphamide	Oncology	$100.0K	2	0.5%	6

Auromedics Pharma, Llc,., imports 4 pharmaceutical products across 3 categories into United States totaling $5.0M.

Auromedics Pharma, Llc,., — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Auromedics Pharma LLC, now known as Eugia US LLC, is a U.S.-based pharmaceutical company specializing in the importation and distribution of generic injectable medications. Established in 2011, the company is headquartered in East Windsor, New Jersey. Eugia US LLC operates as a subsidiary of Eugia Pharma Specialities Limited, an Indian pharmaceutical manufacturer. The company plays a significant role in the U.S. pharmaceutical distribution network by providing hospitals and healthcare facilities with affordable, high-quality generic injectables. Their product portfolio includes a range of antibiotics and oncology drugs, catering to critical therapeutic areas. Eugia US LLC's focus on safety, reliability, and cost-effectiveness has positioned it as a key player in the U.S. healthcare supply chain.

2Distribution Network

Eugia US LLC's distribution network is strategically designed to ensure efficient delivery of pharmaceutical products across the United States. The company's primary warehouse is located in East Windsor, New Jersey, serving as the central hub for operations. From this location, Eugia US LLC manages logistics to various healthcare facilities nationwide, including hospitals, clinics, and pharmacies. The company employs a robust logistics system to maintain product integrity and timely delivery, adhering to stringent regulatory standards. While the primary focus is on the U.S. market, Eugia US LLC's parent company, Eugia Pharma Specialities Limited, has a global presence, indicating potential for international distribution channels.

3Industry Role

Eugia US LLC operates as a pharmaceutical importer and distributor within the United States. By sourcing generic injectable medications from its parent company in India, Eugia Pharma Specialities Limited, the company serves as a conduit between Indian pharmaceutical manufacturers and U.S. healthcare providers. This role involves ensuring that imported products meet U.S. regulatory standards and are effectively distributed to meet market demand. Eugia US LLC's position in the supply chain is crucial for providing cost-effective alternatives to brand-name injectables, thereby enhancing access to essential medications for U.S. patients.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Auromedics Pharma, Llc,.,

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Eugia US LLC's sourcing strategy is highly concentrated, with all imported pharmaceutical products originating from a single supplier: Eugia Pharma Specialities Limited. This single-source dependency presents both opportunities and risks. On the one hand, it allows for streamlined operations and potentially favorable terms due to the volume of business. On the other hand, reliance on a single supplier can expose the company to risks such as supply chain disruptions, quality control issues, or geopolitical factors affecting trade. The shipment data indicates a consistent relationship, with 100 shipments totaling $5.0 million in imports from 2022 to 2026. This consistency suggests a stable and reliable partnership; however, the lack of diversification in suppliers may limit Eugia US LLC's ability to mitigate risks associated with supply chain vulnerabilities.

2Supply Chain Resilience

Eugia US LLC's supply chain resilience is closely tied to the operations of Eugia Pharma Specialities Limited in India. The company's dependence on a single supplier for all imported products means that any disruptions at the manufacturing level—such as production delays, quality control issues, or regulatory challenges—can directly impact Eugia US LLC's ability to meet U.S. market demands. The absence of backup suppliers or alternative sourcing strategies further heightens this vulnerability. Additionally, the reliance on specific shipping routes and ports introduces potential points of failure in the logistics chain. While Eugia Pharma Specialities Limited is likely to adhere to Good Manufacturing Practices (GMP) to ensure product quality, the overall resilience of Eugia US LLC's supply chain is limited by its concentrated sourcing model.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) is the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. The FDA enforces the Federal Food, Drug, and Cosmetic Act (FD&C Act), which sets forth requirements for drug safety, efficacy, and quality. For foreign manufacturers, including those in India, the FDA mandates that facilities register and list their drug products intended for import into the U.S. market. This process ensures that imported drugs meet FDA standards and are safe for U.S. consumers. The FDA also conducts inspections and evaluations to verify compliance with these regulations. Additionally, the FDA's Office of Global Policy and Strategy coordinates with international partners to monitor and enforce compliance with U.S. import regulations.

2Import Licensing & GMP

To import pharmaceutical products into the United States, foreign manufacturers must obtain FDA registration and list their drug products. This process involves submitting detailed information about the manufacturing facility and the products intended for import. The FDA requires that imported drugs comply with Good Manufacturing Practices (GMP), which are standards for ensuring that products are consistently produced and controlled according to quality standards. Recognized GMP certifications include those from the European Union (EU GMP), World Health Organization (WHO GMP), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). These certifications demonstrate that a manufacturer adheres to internationally recognized quality standards, facilitating the acceptance of their products in the U.S. market.

Auromedics Pharma, Llc,., — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Eugia US LLC's product strategy focuses on providing generic injectable medications in the therapeutic areas of advanced antibiotics and oncology. The company's imports from India include ertapenem and meropenem, both advanced antibiotics, as well as pemetrexed and cyclophosphamide, which are used in oncology treatments. The market demand for these products is driven by the need for cost-effective alternatives to brand-name injectables, particularly in hospital settings where injectable medications are commonly used. By sourcing these products from India, Eugia US LLC leverages the country's manufacturing capabilities and cost advantages to meet the needs of U.S. healthcare providers.

2Sourcing Profile

Eugia US LLC's sourcing strategy is centered on importing generic injectable formulations from India, specifically from Eugia Pharma Specialities Limited. The company imports finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, rather than raw active pharmaceutical ingredients (APIs) or bulk drugs. This approach allows Eugia US LLC to offer ready-to-use products that meet U.S. regulatory standards. The focus on generic injectables aligns with the company's mission to provide affordable and high-quality medications to U.S. healthcare facilities.

3Market Positioning

Seller's Guide — How to Become a Supplier to Auromedics Pharma, Llc,.,

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the U.S. market by partnering with Eugia US LLC. The company's existing relationship with Eugia Pharma Specialities Limited demonstrates a successful model for such partnerships. New suppliers would need to meet FDA registration requirements, adhere to GMP standards, and ensure that their products

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Auromedics Pharma, Llc,.,

What products does Auromedics Pharma, Llc,., import from India?

Auromedics Pharma, Llc,., imports 4 pharmaceutical products across 3 categories. Top imports: Ertapenem ($2.5M), Meropenem ($2.2M), Pemetrexed ($200.0K), Cyclophosphamide ($100.0K).

Who supplies pharmaceuticals to Auromedics Pharma, Llc,., from India?

Auromedics Pharma, Llc,., sources from 1 verified Indian suppliers. The primary supplier is Eugia Pharma Specialities Limited (100.0% of imports, $250.0K).

What is Auromedics Pharma, Llc,.,'s total pharmaceutical import value?

Auromedics Pharma, Llc,.,'s total pharmaceutical import value from India is $5.0M, based on 100 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Auromedics Pharma, Llc,., focus on?

Auromedics Pharma, Llc,., imports across 3 categories. The largest: Advanced Antibiotics (94.0%), Advanced Oncology (4.0%), Oncology (2.0%).

Get Full Auromedics Pharma, Llc,., Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 3 company name variants from customs records. For current shipment-level data, contact TransData Nexus.

Formulation	Value	Ships
Cyclophosphamide injection 200MG/ML	$100.0K	2
Daptomycin for injection 500MG MG/vial	$50.0K	1
Eptifibatide injection 75MG/100ML	$50.0K	1
Rocuronium bromide injection 50MG/5ML	$50.0K	1